title: [Reults of treatment with protocols BFM 90 and BFM 95].
abstract: Treatment of acute leukemia is based on the general measures and specific treatment in accordance to the protocols. In the Europe and in Bosnia and Herzegovina BFM protocols are used, and they were developed by German pediatricians- hematologist. Protocols are based on the combination of the medicines (corticosteroids and some citostatics, which are given to the patient according to the exact scheme. These protocols use classification of the diseased according to the risk group diseased belong to.
  
  
  OBJECTIVE
  The aim of this work is to establish which of the protocols, protocol BFM 90 or protocol BFM 95, have more influence in the treatment of the diseased children with lymphoblast leukemia.
  
  
  METHODS
  Patient which were examined were children with ALL and treated on the pediatric clinic in Sarajevo in accordance to the protocols BFM 90 and 95 in the period between 1997 and year 2004. Method used in this study was descriptive analyses based on the inside we had into the available documentation.
  
  
  CONCLUSIONS
  In the study there were 117 children with ALL included. 54 (46,1%) of the children were treated in accordance to the protocol BFM 90, and 63 (53,85 %) of the children were treated in accordance to the protocol BFM 95. There was noticed significant difference of the survival of the diseased children, based on the statistical testing. Children treated in accordance to the protocol BFM 90 there were 24 % of the children who died, and 12,6 % of the children who were treated in accordance to the protocol 95 died.
authors.affiliation: Pedijatrijska Klinika, KCU Sarajevo.
authors.forename: Meliha
authors.initials: M
authors.lastname: Sakić
authors.forename: Jasmina
authors.initials: J
authors.lastname: Berbić-Fazlagić
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin